Co-delivery of paclitaxel (PTX) and docosahexaenoic acid (DHA) by targeting lipid nanoemulsions for cancer therapy
Li B, Tan T, Chu W, Zhang Y, Ye Y, Wang S, Qin Y, Tang J, Cao X
Drug delivery · 39 citations
How it was studied
- Design
- In vitro/mechanistic study (classified by our AI screen)
- Studied in
- People, plus animal or lab work
- Main outcome
- Clinical events such as disease or death
Who paid for it
- Funding
- Independent funding
- Government
- Anhui Province Natural Science Foundation
Based on 1 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2021-12-29 · Drug Deliv · vol. 29 · issue 1 · pp. 75–88
- Publisher
- Taylor & Francis
- Cited
- 53 citations · more than 93% of similar papers · 2.8× the field average
- Impact
- Top 10% most cited in its field
- References
- 54 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Cancer, Lipids, and Metabolism · Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery
- Keywords
- Paclitaxel, Docosahexaenoic acid, Nanocarriers, Cytotoxicity, Pharmacology, Drug delivery, Cancer cell, Toxicity, In vivo, Breast cancer, Apoptosis, Cancer, Cancer research, Chemistry, In vitro, Drug, Medicine, Fatty acid, Biology, Polyunsaturated fatty acid, Biochemistry, Internal medicine
- MeSH
- cell line, tumor, animals, mice, inbred balb c, humans, mice, mice, nude, paclitaxel, folic acid, antineoplastic agents, phytogenic, emulsions, drug carriers, xenograft model antitumor assays, apoptosis, cell survival, dose-response relationship, drug, female, nanoparticles, mcf-7 cells, drug liberation, raw 264.7 cells, tumor-associated macrophages
9 authors
From CN
- Bo LiAnhui Medical University; State Administration of Traditional Chinese Medicine of the People's Republic of China; First Affiliated Hospital of Anhui Medical University
- Tingfei TanAnhui Medical University; State Administration of Traditional Chinese Medicine of the People's Republic of China; First Affiliated Hospital of Anhui Medical University
- Weiwei ChuAnhui Medical University; State Administration of Traditional Chinese Medicine of the People's Republic of China; First Affiliated Hospital of Anhui Medical University
- Ying ZhangAnhui Medical University; First Affiliated Hospital of Anhui Medical University
- Yuanzi YeAnhui Medical University; First Affiliated Hospital of Anhui Medical University
- Shanshan WangAnhui Medical University; State Administration of Traditional Chinese Medicine of the People's Republic of China; First Affiliated Hospital of Anhui Medical University
Abstract
Breast cancer is one of the most common types of cancer in female patients with high morbidity and mortality. Multi-drug chemotherapy has significant advantages in the treatment of malignant tumors, especially in reducing drug toxicity, increasing drug sensitivity and reducing drug resistance. The objective of this research is to fabricate lipid nanoemulsions (LNs) for the co-delivery of PTX and docosahexaenoic acid (DHA) with folic acid (FA) decorating (PTX/DHA-FA-LNs), and investigate the anti-tumor activity of the PTX/DHA-FA-LNs against breast cancer both in vitro and in vivo. PTX/DHA-FA-LNs showed a steady release of PTX and DHA from the drug delivery system (DDS) without any burst effect. Furthermore, the PTX/DHA-FA-LNs exhibited a dose-dependent cytotoxicity and a higher rate of apoptosis as compared with the other groups in MCF-7 cells. The cellular uptake study revealed that this LNs were more readily uptaken by MCF-7 cells and M2 macrophages in vitro. Additionally, the targeted effect of PTX/DHA-FA-LNs was aided by FA receptor-mediated endocytosis, and its cytotoxicity was proportional to the cellular uptake efficiency. The anti-tumor efficiency results showed that PTX/DHA-FA-LNs significant inhibited tumor volume growth, prolonged survival time, and reduced toxicity when compared with the other groups. These results indicated that DHA increases the sensitivity of tumor cells and tumor-associated macrophages (ATM2) to PTX, and synergistic effects of folate modification in breast cancer treatment, thus PTX/DHA-FA-LNs may be a promising nanocarrier for breast cancer treatment.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.